Michael Carducci

918 total citations
24 papers, 707 citations indexed

About

Michael Carducci is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Carducci has authored 24 papers receiving a total of 707 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Carducci's work include Prostate Cancer Treatment and Research (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Epigenetics and DNA Methylation (3 papers). Michael Carducci is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and Epigenetics and DNA Methylation (3 papers). Michael Carducci collaborates with scholars based in United States, United Kingdom and Spain. Michael Carducci's co-authors include Nancy E. Davidson, Sushant K. Kachhap, Antonio C. Wolff, Manuel Hidalgo, Deborah K. Armstrong, John F. Bender, Robert A. Casero, Carol Riley, John H. Fetting and Fernando Ferrer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Michael Carducci

23 papers receiving 682 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Carducci United States	13	436	149	126	88	85	24	707
Jong Ran Lee South Korea	17	404 0.9×	119 0.8×	94 0.7×	84 1.0×	64 0.8×	25	1.1k
Yong‐Kyung Choe South Korea	17	635 1.5×	220 1.5×	171 1.4×	48 0.5×	70 0.8×	30	989
Ruth Sánchez‐Martínez Spain	15	667 1.5×	147 1.0×	404 3.2×	79 0.9×	116 1.4×	21	966
Mary G. McMenamin United States	12	345 0.8×	195 1.3×	95 0.8×	74 0.8×	86 1.0×	17	709
A‐Mei Huang Taiwan	23	735 1.7×	232 1.6×	194 1.5×	56 0.6×	105 1.2×	51	1.2k
Mark Wade United States	13	314 0.7×	150 1.0×	80 0.6×	58 0.7×	68 0.8×	35	632
Kiyoko Shinkai Japan	23	1.0k 2.4×	269 1.8×	152 1.2×	72 0.8×	79 0.9×	41	1.4k
Matthew J. Strouch United States	16	468 1.1×	427 2.9×	272 2.2×	52 0.6×	64 0.8×	24	1.2k
Ming‐Chung Jiang Taiwan	14	647 1.5×	272 1.8×	155 1.2×	79 0.9×	38 0.4×	18	951
Ruilan Yan United States	13	725 1.7×	197 1.3×	166 1.3×	46 0.5×	53 0.6×	19	1.1k

Countries citing papers authored by Michael Carducci

Since Specialization

Citations

This map shows the geographic impact of Michael Carducci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Carducci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Carducci more than expected).

Fields of papers citing papers by Michael Carducci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Carducci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Carducci. The network helps show where Michael Carducci may publish in the future.

Co-authorship network of co-authors of Michael Carducci

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Carducci. A scholar is included among the top collaborators of Michael Carducci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Carducci. Michael Carducci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mendonca, Janet, Olutosin Owoyemi, Marc Rosen, et al.. (2019). Abstract 517: Supraphysiological androgens activate innate immune signaling in prostate cancer. Immunology. 517–517. 1 indexed citations

Shore, Neal D., Matthew R. Smith, Allan Lipton, et al.. (2015). MP73-10 BONE TURNOVER MARKER LEVELS AND OUTCOMES IN MEN WITH PROSTATE CANCER AND BONE METASTASES TREATED WITH BONE ANTIRESORPTIVE AGENTS. The Journal of Urology. 193(4S).

Пили, Роберто, Michael Carducci, Peter de Nully Brown, & Herbert I. Hurwitz. (2014). An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Investigational New Drugs. 32(6). 1258–1268. 10 indexed citations

Azaro, Analía, Jordi Rodón, Michael Carducci, et al.. (2014). Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study. Journal of Medical Cases. 5(11). 603–609. 2 indexed citations

Freedland, Stephen J., Michael Carducci, Nils Kroeger, et al.. (2013). A Double-Blind, Randomized, Neoadjuvant Study of the Tissue Effects of POMx Pills in Men with Prostate Cancer Before Radical Prostatectomy. Cancer Prevention Research. 6(10). 1120–1127. 59 indexed citations

Cleary, James M., Lorrin Yee, Nilofer S. Azad, et al.. (2012). Abstract 2506: A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors. Cancer Research. 72(8_Supplement). 2506–2506. 8 indexed citations

Fu, Chenglai, Whei F. Moriarty, Daniel Keizman, et al.. (2012). Abstract 1913: Epithelial mesenchymal transition: A mechanism of resistance to VEGF pathway inhibition in genitourinary cancers. Cancer Research. 72(8_Supplement). 1913–1913. 1 indexed citations

Liu, Glenn, Yu‐Hui Chen, Jill Kolesar, et al.. (2011). Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urologic Oncology Seminars and Original Investigations. 31(2). 211–218. 20 indexed citations

Shabbeer, Shabana, Ravi Anchoori, Sushant K. Kachhap, et al.. (2009). Fenugreek: A naturally occurring edible spice as an anticancer agent. Cancer Biology & Therapy. 8(3). 272–278. 81 indexed citations

10.

Zhou, Shaoyu, Sushant K. Kachhap, Wenyue Sun, et al.. (2007). Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proceedings of the National Academy of Sciences. 104(18). 7540–7545. 157 indexed citations

11.

Green, Lisa J., Philip Marder, Chad Ray, et al.. (2006). Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor. Clinical Cancer Research. 12(11). 3408–3415. 38 indexed citations

12.

Sung, Jennifer, Qinghua Xia, Wasim H. Chowdhury, et al.. (2006). 794: Valproic Acid Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo. The Journal of Urology. 175(4S). 257–257. 3 indexed citations

13.

Rudin, Charles M., Anjali Desai, Linda Janisch, et al.. (2006). A prospective pharmacogenomic (PG), pharmacodynamic (PD), and pharmacokinetic (PK) study of determinants of erlotinib toxicity. Journal of Clinical Oncology. 24(18_suppl). 3080–3080. 3 indexed citations

14.

Zelent, Arthur, Samuel Waxman, Michael Carducci, et al.. (2004). State of the Translational Science. Clinical Cancer Research. 10(14). 4622–4629. 17 indexed citations

15.

Wilding, George, Michael Carducci, Dechao Yu, et al.. (2004). A Phase 1/11 trial of IV CG7870, a replication-selective, PSA-targeted oncolytic adenovirus (OAV), for the treatment of hormone-refractory, metastatic prostate cancer. Journal of Clinical Oncology. 22(14_suppl). 3036–3036. 1 indexed citations

16.

Lin, Kuo‐Shyan, Kwamena E. Baidoo, Ming‐Kai Chen, et al.. (2004). A New High Affinity Technetium Analogue of Bombesin Containing DTPA as a Pharmacokinetic Modifier. Bioconjugate Chemistry. 15(6). 1416–1423. 17 indexed citations

17.

Wolff, Antonio C., Deborah K. Armstrong, John H. Fetting, et al.. (2003). A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer.. PubMed. 9(16 Pt 1). 5922–8. 94 indexed citations

18.

Wolff, Antonio C., Ross C. Donehower, Michael Carducci, et al.. (2003). Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.. PubMed. 9(10 Pt 1). 3589–97. 65 indexed citations

19.

Ferrer, Fernando, et al.. (2002). Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.. PubMed. 62(9). 2576–82. 49 indexed citations

20.

Poel, Henk G. van der, et al.. (2001). A novel method for the determination of basal gene expression of tissue-specific promoters: An analysis of prostate-specific promoters. Cancer Gene Therapy. 8(12). 927–935. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact